-
1Academic Journal
المؤلفون: Berner, F., Bomze, D., Lichtensteiger, C., Walter, V., Niederer, R., Ali, O.H., Wyss, N., Bauer, J., Freudenmann, L.K., Marcu, A., Wolfschmitt, E.M., Haen, S., Gross, T., Abdou, M.T., Diem, S., Knopfli, S., Sinnberg, T., Hofmeister, K., Cheng, H.W., Toma, M., Klumper, N., Purde, M.T., Pop, O.T., Jochum, A.K., Pascolo, S., Joerger, M., Fruh, M., Jochum, W., Rammensee, H.G., Laubli, H., Holzel, M., Neefjes, J., Walz, J., Flatz, L.
المصدر: Science Immunology
وصف الملف: application/pdf
Relation: lumc-id: 178158745; https://hdl.handle.net/1887/3594269
-
2Academic Journal
المؤلفون: Stanczak, MA, Mantuano, NR, Kirchhammer, N, Sanin, DE, Jacob, F, Coelho, R, Everest-Dass, AV, Wang, J, Trefny, MP, Monaco, G, Barenwaldt, A, Gray, MA, Petrone, A, Kashyap, AS, Glatz, K, Kasenda, B, Normington, K, Broderick, J, Peng, L, Pearce, OMT, Pearce, EL, Bertozzi, CR, Zippelius, A, Laubli, H
Relation: SCIENCE TRANSLATIONAL MEDICINE; ARTN eabj1270; https://qmro.qmul.ac.uk/xmlui/handle/123456789/82525
-
3Academic Journal
المصدر: Laubli, H; Varki, A; Borsig, L (2016). Antimetastatic properties of low molecular weight heparin. Journal of Clinical Oncology, 34(21):2560-2561.
مصطلحات موضوعية: Institute of Physiology, 570 Life sciences, biology, 610 Medicine & health
وصف الملف: application/pdf
Relation: https://www.zora.uzh.ch/id/eprint/130819/1/Laubli_H_Letter_Borsig_2016.pdf; https://www.zora.uzh.ch/id/eprint/130819/8/ZORA130819.pdf; info:pmid/27185851; urn:issn:0732-183X
-
4Academic Journal
المؤلفون: Laubli, H, Spanaus, K, Borsig, L
المصدر: Laubli, H; Spanaus, K; Borsig, L (2009). Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood, 114(20):4583-4591.
مصطلحات موضوعية: Zurich Center for Integrative Human Physiology (ZIHP), Institute of Clinical Chemistry, Institute of Physiology, 570 Life sciences, biology, 610 Medicine & health, 540 Chemistry
وصف الملف: application/pdf
Relation: https://www.zora.uzh.ch/id/eprint/24527/36/24527_manuscript_V.pdf; https://www.zora.uzh.ch/id/eprint/24527/41/24527_Verlag_N.pdf; info:pmid/19779041; urn:issn:0006-4971
-
5Academic Journal
المؤلفون: Berner, F., Bomze, D., Diem, S., Ali, O.H., Fassler, M., Ring, S., Niederer, R., Ackermann, C.J., Baumgaertner, P., Pikor, N., Cruz, C.G., Veen, W. van de, Akdis, M., Nikolaev, S., Laubli, H., Zippelius, A., Hartmann, F., Cheng, H.W., Honger, G., Recher, M., Goldman, J., Cozzi, A., Fruk, M., Neefjes, J., Driessen, C., Ludewig, B., Hegazy, A.N., Jochum, W., Speiser, D.E., Flatz, L.
المصدر: JAMA Oncology
Relation: lumc-id: 63854067; https://hdl.handle.net/1887/120728
-
6Academic Journal
المؤلفون: Pearce, OMT, Laubli, H
وصف الملف: 638 - 639
Relation: GLYCOBIOLOGY; https://qmro.qmul.ac.uk/xmlui/handle/123456789/68126
-
7
-
8Academic Journal
المؤلفون: Laubli, H., Tzankov, A., Juskevicius, D., Degen, L., Rochlitz, C., Stenner-Liewen, F.
Relation: Laubli, H. and Tzankov, A. and Juskevicius, D. and Degen, L. and Rochlitz, C. and Stenner-Liewen, F. (2016) Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-transplant lymphoproliferative disorder. Leukemia & Lymphoma, 57 (4). pp. 945-948.; info:pmid/26295731; urn:ISSN:1029-2403
-
9Academic Journal
-
10Academic Journal
المؤلفون: Joerger, Markus, Calvo, Emiliano, Laubli, Heinz, Lopez, Juanita, Alonso-Casal, Guzman, Corral de la Fuente, Elena, GARRALDA, Elena
المساهمون: Institut Català de la Salut, Joerger M Department of Medical Oncology & Hematology, Cantonal Hospital, St. Gallen, Switzerland. Calvo E, Corral de la Fuente E START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain. Laubli H Department of Medical Oncology, University Hospital Basel, Basel, Switzerland. Lopez J Institute of Cancer Research, Royal Marsden Hospital, London, UK. Alonso G, Garralda E Early Drug Development Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus
المصدر: Scientia
مصطلحات موضوعية: Cèl·lules T, Càncer - Tractament, Immunoglobulines, DISEASES::Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANATOMY::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies, ENFERMEDADES::neoplasias, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, ANATOMÍA::células::células sanguíneas::leucocitos::leucocitos mononucleares::linfocitos::linfocitos T, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos
وصف الملف: application/pdf
Relation: Journal for ImmunoTherapy of Cancer;11(11); https://doi.org/10.1136/jitc-2023-007784; Joerger M, Calvo E, Laubli H, Lopez J, Alonso G, Corral De La Fuente E, et al. Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. J Immunother Cancer. 2023 Nov;11(11):e007784.; https://hdl.handle.net/11351/10859
Full Text Finder